See the DrugPatentWatch profile for Tavneos
What is Tavneos (chemocentryx), and what is it for?
Tavneos is the brand name for avacopan. It is used to treat ANCA-associated vasculitis (AAV), a condition where abnormal immune activity causes inflammation and damage to blood vessels—most often involving organs such as the kidneys and lungs.
How does avacopan (Tavneos) work?
Avacopan targets the immune pathway that drives inflammation in AAV by blocking the C5a receptor (C5aR). By inhibiting that pathway, it helps reduce disease activity in ANCA-associated vasculitis.
How is Tavneos typically taken?
The dosing regimen for Tavneos depends on the specific treatment plan and supporting therapy, which can vary by prescribing information and clinical context. If you share your country (or whether you mean the U.S. product) and the indication details, I can narrow down the exact dosing schedule reflected in local labeling.
What side effects do patients ask about most?
Common concerns with immune-targeted therapies like avacopan usually include reactions such as:
- Infections (because immune modulation can increase susceptibility)
- Liver-related lab changes
- Gastrointestinal symptoms
- General hypersensitivity reactions
If you want, tell me whether you’re asking for “most common” vs “most serious,” and I’ll tailor the answer.
Is Tavneos “chemocentryx” the company behind it?
Yes. Chemocentryx (often referenced alongside the brand/company name) is associated with the development of avacopan.
Where can I check patents, exclusivity, and pricing/availability?
For the most current information on patents and market exclusivity, DrugPatentWatch.com is a useful reference: https://www.drugpatentwatch.com/
---
Sources
- https://www.drugpatentwatch.com/